Corning Jerry Pharmaceutical-B (09966) continued to drop 6%, and the stock closed down nearly 45% yesterday. As of press release, it decreased by 6.08% to HK$2.47, with a turnover of HK$396.06 million.
The Zhitong Finance App learned that Corning Jerry Pharmaceutical-B (09966) continued to fall 6%, and the stock closed down nearly 45% yesterday. As of press release, it decreased by 6.08% to HK$2.47, with a turnover of HK$396.06 million.
According to the news, Corning Jerry Pharmaceuticals announced a few days ago that the KN046-303 test has reached the pre-set number of deaths. Data analysis shows that the overall survival (OS) results have not reached the intended statistical end point. Analysts pointed out that for Corning Jerry, the impact of the KN046-303 failure was significant. The market once expected KN046 to have the potential to treat thymic cancer, pancreatic cancer, tri-yin breast cancer, and other cancers that do not respond to PD-1 alone. According to reports, Corning Jerry Pharmaceuticals' only commercial product is Envolizumab subcutaneous injection. KN046, which was thwarted this time, is its next product that is expected to be commercialized, so the market places particular importance on it.